tetano
Editor, Senior Moderator
Pharmacol Res Perspect
. 2022 Feb;10(1):e00909.
doi: 10.1002/prp2.909.
Molnupiravir: A new candidate for COVID-19 treatment
Fariba Pourkarim[SUP] 1 2 [/SUP], Samira Pourtaghi-Anvarian[SUP] 1 2 [/SUP], Haleh Rezaee[SUP] 2 3 [/SUP]
Affiliations
Abstract
The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID-19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.
Keywords: COVID-19 treatment; EIDD-2801; MK-4482; antiviral drugs; molnupiravir; novel coronavirus disease 2019.
. 2022 Feb;10(1):e00909.
doi: 10.1002/prp2.909.
Molnupiravir: A new candidate for COVID-19 treatment
Fariba Pourkarim[SUP] 1 2 [/SUP], Samira Pourtaghi-Anvarian[SUP] 1 2 [/SUP], Haleh Rezaee[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34968008
- DOI: 10.1002/prp2.909
Abstract
The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID-19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.
Keywords: COVID-19 treatment; EIDD-2801; MK-4482; antiviral drugs; molnupiravir; novel coronavirus disease 2019.
